Treats pulmonary tuberculosis (TB) resistant. Sold as Pretomanid. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Pretomanid (sold as Pretomanid), first approved Aug 14, 2019, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Pretomanid | Part D | $82K | +51% | 31 |
| Study of Combinations of Novel Promising Drugs for Pulmonary TuberculosisTuberculosis, Pulmonary · TASK Applied Science | Phase 2 | Not yet recruiting | Aug 19, 2026 |
| Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TBTuberculosis, Pulmonary · Global Alliance for TB Drug Development | Phase 2 | Recruiting | Jun 26, 2026 |
| Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary TuberculosisDrug Susceptible Pulmonary Tuberculosis · Gates Medical Research Institute | Phase 2 | Recruiting | Apr 13, 2026 |
| BPaLMZ for TB MeningitisTuberculous Meningitis, HIV · David Boulware | Phase 2 | Recruiting | Nov 13, 2025 |
| A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary TuberculosisRifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis · Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | Recruiting | Oct 7, 2025 |
| A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary TuberculosisRifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis, Type 2 Diabetes Mellitus (T2DM) · Wuhan Pulmonary Hospital | — | Not yet recruiting | Sep 25, 2025 |
| A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant TuberculosisEfficacy and Safety · Wuhan Pulmonary Hospital | Not applicable | Not yet recruiting | Aug 17, 2025 |
| A PAN-USR TB Multi-Center TrialPulmonary Tuberculosis · Shenzhen Third People's Hospital | Phase 3 | Recruiting | Apr 1, 2025 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Aug 14, 2019 | PretomanidNDA 212862 · New molecular entity | Mylan Ireland Ltd | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA